After 48 h, cells were incubated without HDAC inhibitor (growth media containing <2% DMSO) or with SHI-1: 2 (10M in growth media containing <2% DMSO) or SAHA (10M in growth media containing <2% DMSO) for another 24 h, harvested, and lysed, as described earlier

After 48 h, cells were incubated without HDAC inhibitor (growth media containing <2% DMSO) or with SHI-1: 2 (10M in growth media containing <2% DMSO) or SAHA (10M in growth media containing <2% DMSO) for another 24 h, harvested, and lysed, as described earlier. example, histone 3 (H3) lysine 9 can be methylated or acetylated, with methylation linked to repression of transcription and acetylation correlated with transcriptional upregulation. 2In contrast, H3 lysine 4 methylation BMY 7378 or acetylation are both associated with upregulation of gene expression. 3, 4As these two examples illustrate, the interplay between methylation and acetylation combine to regulate gene expression. Histone methyltransferase and histone demethylase proteins govern methylation, whereas histone acetyltransferase and histone deacetylase proteins control acetylation. Remarkably, histone demethylase and deacetylase enzymes are found in the same cellular complexes. For example , the CoREST and NuRD corepressor complexes contain two deacetylase isoforms, histone deacetylase 1 (HDAC1) and HDAC2, and one demethylase protein, lysine specific demethylase1 (LSD1). 5In addition, both histone demethylases and deacetylases are aberrantly overexpressed in many diseases, including cancer. 611Given the co-overexpression and colocalization of HDAC and LSD1, understanding the functional relationship between these epigenetic enzymes will reveal new cell biology and mechanisms of disease progression. Inhibitors of HDAC and LSD1 have been helpful in studying the role of histone modifications in gene expression. Gene profiling studies with HDAC inhibitors revealed that HDAC proteins regulate genes linked to cell cycle (p21 and p27, for example) and apoptosis (Fas, FasL, TRAIL, and DR-5, for example), which are dysfunctional in cancers. 1214With their role in cancer formation, four HDAC inhibitors have been approved by the FDA as cancer therapeutics, including Vorinostat (SAHA, Suberoyl Anilide Hydroxamic Acid, Zolinza) for the treatment of cutaneous T-cell lymphoma. 15Related to the methylation and acetylation crosstalk, HDAC inhibitors influenced H3 methylation, 16which is consistent with a functional link between HDAC and LSD1. In fact , coadministration of HDAC and LSD1 inhibitors shows some promise as a combination anticancer therapy. 17The possible use of HDAC and LSD1 inhibitors for cancer treatment further highlights the importance for studying the functional interplay between histone methylation and acetylation. Here, we studied the functional link between histone methylation and acetylation by identifying LSD1 as a cellular substrate of HDAC1 using a previously developed mutant trapping approach. 18The data indicated that HDAC1-mediated deacetylation regulates the acetylation state, H3 substrate binding, and gene repression function of LSD1. Therefore , the study uncovered a novel crosstalk between HDAC1 and LSD1. Considering the HDAC BMY 7378 inhibitor-mediated derepression of LSD1 target genes identified here, HDAC inhibitors likely block the aberrant activity of both HDAC1 and LSD1 in cancer. This work highlights the importance of characterizing the functional interaction of HDAC1 and LSD1 in physiological and pathological conditions, which will assist in drug development targeting epigenetic enzymes. == RESULTS AND DISCUSSION == HDAC1 regulates gene expression by deacetylating histone proteins. 19Beyond histones, the large and growing list of acetylated proteins20implicates nonhistone proteins as substrates of HDAC proteins. BMY 7378 In fact several nonhistone substrates have been identified for two HDAC family members, HDAC6 and HDAC8, using genetic and pharmacological methods. 2123However, genetic and pharmacological methods have been ineffective with HDAC1 due to compensation by HDAC2 and lack of HDAC1-selective inhibitors. Consequently, only a few validated substrates of HDAC1 are reported. 24, 25Given the steadily growing list of acetylated proteins, HDAC1 is likely to have additional nonhistone substrates. New strategies to identify HDAC1 substrates are needed to characterize the full biological activities of HDAC1. Substrate trapping mutants have been widely used to identify phosphatase substrates. 18In the BMY 7378 trapping strategy, catalytically inactive mutant enzyme binds to substrates relatively stably compared to wild type (Figure 1A, B), allowing effective isolation. Given the significance of identifying nonhistone substrates to explore the role of HDAC1 in the cell, here we used inactive HDAC mutants as traps to identify new substrates from HEK293 cells. == Figure 1 . == Substrate trapping by HDAC1 mutants in HEK293 cells. (A) Catalytically active wild type (WT) HDAC1 binds substrates transiently. (B) Inactive HDAC1 mutants (MT) bind more stably, which allows immunoprecipitation and TRIM13 identification of novel substrates. (C) After immunoprecipitation, bound proteins were analyzed by SDS-PAGE. Protein bands present only in the mutant HDAC1 (MT) could be potential substrates (see arrows), which was further confirmed by using an active site HDAC inhibitor (Inh) as a competitor. (D) Wild type (WT) or C151A mutant HDAC1 were expressed as Flag-tagged proteins in SAHA-treated HEK293 cells, immunoprecipitated with anti-Flag agarose in the absence or presence of SAHA, separated by 10% SDS-PAGE, and visualized with Sypro Ruby total protein stain. Arrows indicate immunoprecipitated HDAC1 along with possible substrates (p38, p55, and.